Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: Long-term follow-up in 35 cases

Leukemia and Lymphoma

Volumn 30, Issue 3-4, 1998, Pages 313-324

  Moreau, Philippe ^a   Milpied, Noël ^a   Rapp, Marie José ^a   Moreau, Anne ^a   Bourdin, Sylvain ^a   Mahe, Marc Antoine ^a   Dupas, Benoît ^a   Le Tortorec, Stéphane ^a   Hamidou, Mohamed ^a   Maisoneuve, Hervé ^a   Mahe, Béatrice ^a   Bulabois, Claude Eric ^a   Morineau, Nadine ^a   Jardel, Henri ^a   Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

Autologous stem cell transplantation; Hodgkin's disease

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; VINBLASTINE;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER STAGING; CAUSE OF DEATH; CHEMOSENSITIVITY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL TIME; WHOLE BODY RADIATION;

EID: 7344251178     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057544     Document Type: Article

References (53)

1. Hoppe, R. T. (1991). Development of effective salvage treatment programs for Hodgkin's disease: An ongoing challenge. Blood, 77, 2093-2095.
2. Nademanee, A., O'Donnell, M. R., Snyder, D. S., et al. (1995). High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood, 85, 1381-1390.
3. Jagannath, S., Armitage, J. O., Dicke, K. A., et al. (1989). Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, etoposide with autotransplantation for relapsed Hodgkin's disease. J Clin Oncol, 7, 179-185.
4. Chopra, R., McMillan, A. K., Linch, D. C., et al. (1993). The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood, 81, 1137-1145.
5. Reece, D. E., Connors, J. M., Spinelli, J. J., et al. (1994). Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood, 83, 1193-1199.
6. Desch, C. E., Lasala, M. R., Smith, T. J., et al. (1992). The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clinical Oncol, 10, 200-209.
7. Yuen, A. R., Rosenberg, S. A., Hoppe, R. T., et al (1997). Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89, 814-822.
8. Horning, S. J., Chao, N. J., Negrin, R. S., et al. (1997). High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood, 89, 801-813.
9. Linch, D. C., Winfield, D., Goldstone, A. H., et al. (1993). Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet, 341, 1051-1054.
10. Bierman, P. J., Vose, J. M. and Armitage, J. O. (1994). Autologous transplantation for Hodgkin's disease: Coming of age? Blood, 83, 1161-1164.
11. Carella, A. M., Carlier, P., Congiu, A., et al (1991). Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP-ABVD protocol. Bone Marrow Transplant, 8, 99-103.
12. Moreau, P., Milpied, N., Méchinaud-Lacroix, F., et al. (1993). Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leuk Lymph, 12, 51-58.
13. Fleury, J., Legros, M., Colombat, P., et al. (1996). High-dose therapy and autologous bone marrow transplantation in first complete or partial response for poor prognosis Hodgkin's disease. Leuk Lymph, 20, 259-266.
14. Sureda, A., Mataix, R., Hernandez-Navarro, et al. (1997). Autologous stem cell transplantation for poor-prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO coopertive group. Bone Marrow Transplant, 20, 283-288.
15. Straus, D. J., Gaynor, J. J., Myers, J., et al. (1990). Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol, 8, 1173-1186.
16. Gobbi, P. G., Cavalli, C., Federico, M., et al. (1986). Hodgkin's disease prognosis: A directly predictive equation. Lancet, i, 675-679.
17. Hasenclever, D. and Diehl, V. (1996). The international prognostic factors project on advanced Hodgkin's disease: a prognostic index, but no very high risk group. Ann Oncol, 7 (Suppl3), 21a (abstr).
18. Proctor, S. J., Taylor, P., Donnan, P., et al. (1991). A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer, 27, 624-629.
19. Wagstaff, J., Gregory, W. M., Swindell, R., et al. (1988). Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centers. Br J Cancer, 58, 487-492.
20. Kuentz, M., Reyes, F., Brun, B., et al. (1983). Early response to chemotherapy as a prognostic factor in Hodgkin's disease. Cancer, 52, 780-785.
21. Levis, A., Vitolo, U., Ciocca Vasino, A., et al. (1987). Predictive value of early response to chemotherapy in high risk stages II and III Hodgkin's disease. Cancer, 60, 1713-1719.
22. Santoro, A., Bonadona, G., Bonfante, V., et al. (1982). Alternating drug combination in the treatment of advanced Hodgkin's disease. N Engl J Med, 306, 770-775.
23. Lukes, R. J. and Buttler, J. J. (1966). The pathology and nomenclature for Hodgkin's disease. Cancer Res, 26, 1063-1081.
24. Linch, D. C., Knott, L. J., Patterson, K. G., et al. (1982). Bone marrow processing and cryopreservation. J Clin Pathol, 35, 186-190.
25. Fermand, J. P., Lévy, Y., Gerota, et al. (1989). Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous grafts. Blood, 73, 20-23.
26. Moreau. P., LeTortorec, S., Mahé, B., et al. (1994). Granulocyte colony-stimulating factor administered from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization. Nouv Rev Fr Hematol, 36, 455-458.
27. Faucher, C., LeCorroler, A. G., Chabannon, C., et al. (1996). Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant, 17, 533-536.
28. Chen, J. L., Osborne, B. M. and Buttler, J. J. (1987). Residual fibrous masses in treated Hodgkin's disease. Cancer, 60, 407-413.
29. Kaplan, E. L. and Meier, P. (1958). Non parametric estimation from incomplete observations. J Am Stat Assoc, 53, 157-181.
30. Burgers, J. M. V., Somers, R., Henry-Amar, M., et al. (1991). Management of relapse and survival in advanced stage Hodgkin's disease: The EORTC experience. Ann Oncol, 2 (suppl. 2), 63-66.
31. Tucker, M. A., Coleman, C. N., Cox, R. S., et al. (1988). Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med, 318, 76-81.
32. Viviani, S., Bonadonna, G., Santoro, A., et al. (1996). Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol, 14, 1421-1430.
33. Salloum, E., Doria, R., Schubert, W., et al. (1996). Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol, 14, 2435-2443.
34. Miller, J. S., Arthur, D. C., Litz, C. E., et al. (1994). Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood, 83, 3780-3786.
35. Traweek, T., Slovak, M. L., Nademanee, A. P., et al. (1994). Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood, 84, 957-963.
36. Darrington, D. L., Vose, J. M., Anderson, J. R., et al. (1994). Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol, 12, 2527-2534.
37. Stone, R. M., Neuberg, D., Soiffer, R., et al. (1994). Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol, 12, 2535-2542.
38. Pihkala, J., Saarinen, U. M., Lundström, U., et al. (1994). Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant, 13, 149-155.
39. Hancock, S. L., Tucker, M. A and Hoppe, R. T. (1993). Factors affecting late mortality from heart after treatment for Hodgkin's disease. JAMA, 270, 1949-1955.
40. Corn, B. W., Trock, B. J. and Goodman, R. L. (1990). Irradiation-related ischemic heart disease. J Clin Oncol, 8, 741-750.
41. Phillips, G. L., Wolff, S. N., Herzig, R. H., et al. (1989). Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood, 73, 2086-2092.
42. Horning, S. J., Negrin, R. S., Chao, N., et al. (1994). Fractionated total-body irradiation, etoposide and cyclophosphamide plus autografting in Hodgkin's disease and nonHodgkin's lymphoma. J Clin Oncol, 12, 2552-2558.
43. Bonnadonna, G., Santoro, A., Gianni, A. M., et al. (1991). Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol, 2 (Suppl1), 9-16.
44. Kunkel, L., Tung, P., Ireland, P., Schiller, G. and Territo, M. (1995). Two-staged autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol, 14, 322a (abstr).
45. Ahmed, T., Lake, D. E., Beer, M., et al. (1997). Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplant, 19, 449-454.
46. Bartlett, N. L., Rosenberg, S. A., Hoppe, R. T., et al. (1995). Brief chemotherapy, Stanford V. and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol, 13, 1080-1088.
47. Canellos, G. P., Anderson, J. R., Propert, K. J., et al. (1992). Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl Med, 327, 1478-1484.
48. Hancock, B. W., Vaughan Hudson, G., Vaughan Hudson, B., et al. (1992). LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation trial. J Clin Oncol, 10, 1252-1258.
49. Longo, D. L., Duffey, P. L., DeVita, V. T., et al. (1991). Treatment of advanced-stage Hodgkin's disease: Alternating non crossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol, 9, 1409-1420.
50. Fermé, C., Lepage, E., Brice, P., et al. (1993). Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients. Int J Radiation Oncology Biol Phys, 26, 397-405.
51. Somers, R., Carde, P., Henry-Amar, H., et al. (1994). A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma cooperative group and group Pierre-et-Marie Curie controlled clinical trial. J Clin Oncol, 12, 279-287.
52. Connors, J. M., Klimo, P., Adams, G., et al. (1997). Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol, 15, 1638-1645.
53. Duggan, D., Petroni, G., Johnson, J., et al. (1997). MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol, 16, 12a (abstract).